Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Withdrawn 2Recruiting 2Not yet recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 66Genitourinary 35Other hematologic neoplasm 22Thoracic 2Myeloid 2Gynecologic 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Breast 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Prednisone × Dermatologic × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡